Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion. -- Ignore unavailable to you. Want to Upgrade?

To: SSP who wrote (81523)	3/8/2001 5:23:46 PM
From: StocksDATsoar	Read Replies (1) \| Respond to of 150070

INTC warns of lower earnings..YIIIIIIIIKESSSSSSSSSSSSSSS THERE GOES THE MARKETS... WHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHHAT!

To: SSP who wrote (81523)	3/8/2001 7:37:48 PM
From: lindao	Read Replies (2) \| Respond to of 150070

Vitro Files Patent: May Prevent 'Mad Cow Disease' Spread to Biotech Products Jump to first matched term A STORY WITH SIZZLE! LITTLETON, Colo., March 8 /PRNewswire/ -- Vitro Diagnostics, Inc. (OTC Bulletin Board: VODG) announced today that it has filed a patent application with the United States Patent and Trademark Office entitled "Defined Medium for the Culture of Human Cells." This filing seeks patent protection for the Company's specially formulated, liquid cell culture medium, which can be used to grow human cells in a manner that ensures their protection against infection by "Mad Cow Disease." Biotechnology scientists often grow their product-producing cells in a medium containing fetal bovine serum. With the ever-increasing spread of "Mad Cow Disease," there is a high demand for media that can guarantee that "Mad Cow Disease" would not be spread via therapeutic interventions. The Company has derived a specialty medium that is optimal for the proliferation of human cells in cell culture. This medium is serum-free and contains clearly defined components that are available from non-animal sources. This medium is necessary for production of biopharmaceutical materials that originate from cultured human cells. Current FDA guidelines suggest the use of defined, serum-free culture medium to produce biological therapeutic products because of concerns regarding the introduction of contamination into drug products. The Company's product pipeline includes various forms of purified FSH and related products for use in the treatment of infertility. A plan for the approval of its first product, VITROPIN(TM), is under review by the FDA. VITROPIN(TM) is a highly purified form of urinary FSH produced through the Company's patented method. Additional patent-pending products include VITROPIN-C(TM), custom FSH that reduces side effects of current products, VITROPIN-V(TM), a breakthrough FSH product produced from a proprietary immortalized cell line, and VITROJECT(TM), a novel drug injection device for administration of FSH and other drugs. VITROCELL-X(TM) is the designation of a series of immortalized cell lines in which "X" represents the organ from which the cell line was derived, and each of which produces "natural therapeutic" products. For example, "VITROCELL-PG(TM)" is a cell line derived from the human pituitary gland that produces FSH. VITROCELL-X(TM) cell lines are produced by the Company's proprietary platform technology method, VITROCELL-X(TM) CELL IMMORTALIZATION TECHNOLOGY, which uses the controlled over-expression of specific genes to produce cellular immortalization. The newly discovered medium that is the subject of the recently filed patent application would be used in the production of "Naturally Pure Therapeutics"(TM) from immortalized human cells. Additional information may be accessed through the Company's web site at www.vitrodiag.com

To: SSP who wrote (81523)	3/8/2001 10:44:16 PM
From: asker2	Respond to of 150070

DCTG news after the close... going for the gold!? maybe a Whaaaaaaattt.. for tomorrow... software company now owns 100% of site selling gold nuggets..??? .035 x .05 ... 52 week .016 x 6.00 ... o/s 15.8mm float 7.1mm ... 55% insider owned... biz.yahoo.com bigcharts.com Delta Capital Technologies, Inc. Acquires Minority Interest Of Au-online.com THURSDAY, MARCH 08, 2001 4:14 PM - BusinessWire WILMINGTON, Delaware, Mar 8, 2001 (BUSINESS:DCTG) reports that further to the Company's news release of February 24, 2001, the Company has elected to exercise it's option to acquire the remaining minority interest of the outstanding shares of Au-online.com. Pursuant to the terms of its agreement, Delta will now issue a total of 8,000,000 shares in exchange for all the issued and outstanding shares of Au-online.com. In connection with the acquisition, Delta will purchase additional inventory and immediately implement an aggressive web site integration program to gain maximum market exposure. The unique Au-Online.com e-Commerce business model for the venture provides Au-online.com the exclusive purchase and marketing rights for all gold-nugget production originating from a group of claims in the Ten Mile district of north-central Nevada held by Kayzak Resources of Winnemucca, Nevada. The nuggets will be marketed through the company's web site at au-online.com. -------------------------------------------------------------- Personally, I think the nuggets are cool... I might even buy one... I just don't see the software connection... but who cares if we make $$$... ... if nothing else is happening tomorrow... this one is moveable.. IMHO fwiw

To: SSP who wrote (81523)	3/28/2001 2:10:30 AM
From: Jim Bishop	Read Replies (1) \| Respond to of 150070

MDCH LIST stock news Tuesday: Tuesday March 27, 9:31 am Eastern Time Press Release Meditech Re-Files SB-2 Registration Statement -- Completes Zorex Package Development. SCOTTSDALE, Ariz.--(BW HealthWire)--March 27, 2001--Meditech Pharmaceuticals Inc. (OTC BB:MDCH) Tuesday announced that it has filed a Form SB-2 Registration Statement with the Securities and Exchange Commission. This filing replaces the Form SB-2 previously withdrawn in February. The company also announced that it has completed development of the retail package for Zorex, its cold sore product. Steven Kern, Meditech's chief operating officer stated, ``I am pleased that we are moving forward with the SB-2 filing. I am also very pleased with the progress of the Zorex package development. The package has been reviewed by regulatory counsel for compliance with applicable laws. The final package will be ready shortly after the ICAR conference in Seattle on April 9, 2001.'' Meditech is a drug development company focused on human, veterinary and agricultural antimicrobial agents. -------------------------------------------------------------------------------- Contact: Meditech Pharmaceuticals Inc., Scottsdale Steven Kern, 480/614-2874 Fax: 480/614-0560 mdch.net mdch@mdch.net